focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Sentiment is low, with the share price down due to RiverFort dumping shares, market confidence has dropped (presumably because RF’s own SP has tanked) ….. We have been here before and whilst we can see how quickly the SP can fall, history has also showed us how fast it can rise. And whilst our SP doesn’t represent this, Sareum hasn’t had this much momentum before which can be categorised by Steven parker in a previous conference saying “this is the most exiting period of sareum’s history”
737 which was left idle for years has now been licenced again and this time we should see some substance behind the promises towards the milestone payments. Also, many shareholders are questioning why 1801 hasn’t been licenced yet as Sareum’s business model has always been get them through pre-clinical and then licence them. However, these are unprecedented market conditions, with international conflicts and recovering markets after covid, borrowing money is very difficult and many Pharmaceutical companies are having to think twice about where to invest their money in order to protect their cashflow.
We have already seen positive news regarding the food part of the trial for 1801 with no significant side affects. If I worked for a big pharma then I too would wait for the conclusive data from the p1 trial before thinking about licencing 1801, and I can imagine the feedback from these potential licence partners was “show us the data and then we’ll talk”.
In the short term what would prove positive for the SP would be get shot of Riverfort and increase the companies exposure. Whilst I’m optimistic that these low levels will be a thing of the past when data comes out in the summer, having a higher market cap will ensure a better licence deal for 1801.
I noticed that today on Endpoints a survey by Harris has shown that oncologists want more options for treating late stage NSCLC (Non Small Cell Lung Cancer). SRA737 went up against NSCLC when with Sierra. Just wondering if it will be further advanced with the new licencee. The oncologists stated than none of the current immuno therapies were rated as excellent. Maybe we can change that??
A lot to look forward to in the next few months, hopefully we hear back about the CEOL application before mid March, however I’m quietly optimistic about this due to the fact that earlier in December they signed the first codeveloped sustainable lithium project in regards to working with indigenous groups. If this doesn’t show the government how Cleantech is willing to work with vulnerable stakeholders, then nothing will. I would imagine we hear something about the DLE plant in the next couple of weeks aswell as hearing about how the recent drilling campaigns are going. Then following this we should have the PFS which will open negotiations with interested partners. If this news flow isn’t delayed then we should see over 50 again in no time. So nows a good time to buy whilst it’s cheap.
To add to HBD’s comment, we have the patent for the molecule inside the capsule In China as of the 26th June earlier this year whilst other patents such as in Europe and the US were still under review. However the fact that the patent was granted in China is a good indication that it should be approved in other parts of the world. There are multiple TYK2/JAK1 inhibitors around the world but all of them have different molecular properties and usually go up against different indications.
I have to admit I’m very impressed in Cleantech, and I can feel the BOD’s frustration on how undervalued this stock is despite the traction of positive news. Although this has probably already been mentioned on this BB Aldo has already expressed high levels of interest from third parties wanting a piece of the pie but wants to hold off until there’s more cash in liquidation to get a better deal
Yep it's the MM's manipulating the market
Not to p*** on anyone's bombfire here, but the only thing predictable about this share is its unpredictability. I stupidly sold some when it drifted down a 4-5% the other day and lost a little because my average was £3.60 so lost a few grand which is making me kick myself atm Thinking that maybe it would retrace back to sub £3. What brought me back, is that I've been invested with this share for a year and I would kick myself If I had sold and woke up to an RNS about the JV and the SP doubled or more.